Amgen Inc.
General ticker "AMGN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $155.3B (TTM average)
Amgen Inc. follows the US Stock Market performance with the rate: 29.9%.
Estimated limits based on current volatility of 1.0%: low 338.71$, high 345.77$
Factors to consider:
- Company included in S&P500 list
- Company included in NASDAQ-100 index
- Company pays dividends (irregularly): last record date 2025-08-22, amount 2.38$ (Y0.70%)
- Total employees count: 28000 as of 2024
- US accounted for 8.6% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Cybersecurity threats, Economic downturns and volatility, Manufacturing disruptions, Acquisition/divestiture risks, Climate change and natural disasters
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [254.51$, 345.82$]
- 2025-12-31 to 2026-12-31 estimated range: [265.43$, 360.68$]
Financial Metrics affecting the AMGN estimates:
- Negative: with PPE of 13.2 at the end of fiscal year the price was very high
- Positive: Operating profit margin, % of 21.71 > 18.64
- Positive: Industry operating profit margin (median), % of 20.85 > 9.92
- Positive: 6.82 < Operating cash flow per share per price, % of 8.11
- Positive: Industry earnings per price (median), % of 5.67 > 4.43
- Positive: Inventory ratio change, % of -7.93 <= -0.75
- Negative: Shareholder equity ratio, % of 6.40 <= 18.93
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 4.26
Short-term AMGN quotes
Long-term AMGN plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $26,323.00MM | $28,190.00MM | $33,424.00MM |
| Operating Expenses | $16,757.00MM | $20,293.00MM | $26,166.00MM |
| Operating Income | $9,566.00MM | $7,897.00MM | $7,258.00MM |
| Non-Operating Income | $-2,220.00MM | $-42.00MM | $-2,649.00MM |
| Interest Expense | $1,406.00MM | $2,875.00MM | $3,155.00MM |
| R&D Expense | $4,434.00MM | $4,784.00MM | $5,964.00MM |
| Income(Loss) | $7,346.00MM | $7,855.00MM | $4,609.00MM |
| Taxes | $794.00MM | $1,138.00MM | $519.00MM |
| Profit(Loss)* | $6,552.00MM | $6,717.00MM | $4,090.00MM |
| Stockholders Equity | $3,661.00MM | $6,232.00MM | $5,877.00MM |
| Inventory | $4,930.00MM | $9,518.00MM | $6,998.00MM |
| Assets | $65,121.00MM | $97,154.00MM | $91,839.00MM |
| Operating Cash Flow | $9,721.00MM | $8,471.00MM | $11,490.00MM |
| Capital expenditure | $936.00MM | $1,112.00MM | $1,096.00MM |
| Investing Cash Flow | $-6,044.00MM | $-26,204.00MM | $-1,046.00MM |
| Financing Cash Flow | $-4,037.00MM | $21,048.00MM | $-9,415.00MM |
| Earnings Per Share** | $12.18 | $12.56 | $7.56 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.